サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1304444

ニコチンガムの世界市場-2023年～2030年

Global Nicotine Gum Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 190 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ニコチンガムの世界市場-2023年～2030年
出版日: 2023年07月07日
発行: DataM Intelligence
ページ情報: 英文 190 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界のニコチンガム市場は、2022年に12億米ドルに達し、2030年には18億米ドルに達することで有利な成長を示すと予測されています。予測期間2023-2030年のCAGRは5.7%です。禁煙を支援するFDA認可薬はニコチンガムです。このガムは、禁煙欲求が強い場合に必要に応じて、あるいは禁断症状を防ぐためにニコチンパッチと併用して2時間ごとに使用することができ、ニコチンの市場規模を押し上げます。

さらに、ガムは禁煙補助薬として知られる薬物グループの一員です。一種のフレーバー付きチューインガムで、ニコチンを口腔内に放出し、喫煙者の血流に吸収され、喫煙衝動を抑えます。世界保健機関（WHO）や米国疾病予防管理センター（CDC）などの保健機関は、喫煙者がニコチンガムを摂取するようになった結果、COVID-19感染から回復するための予防措置として禁煙を勧めています。

ニコチンの供給と吸収はニコチン中毒において重要な役割を果たします。禁煙しようとすると、体がニコチンに依存するようになるため、禁断症状が生じることがあります。様々なフレーバーを持つニコチンガムは、コントロールされた服用方法を提供し、禁煙体験を高めながらニコチンの離脱を管理するのに役立ち、ニコチンガム市場規模を牽引しています。

市場力学

禁煙キャンペーンの推進が市場拡大を牽引

ニコチンガム市場の成長は、都市化の進展、ニコチンガムの開発など継続的な製品革新、広範な研究開発努力などいくつかの要因によって推進されています。新興国および先進国の政府および非政府組織（NGO）は、個人、特に若者がタバコ中毒を克服できるよう、ニコチンガムやその他のニコチン代替製品を含む禁煙補助製品の使用を積極的に推進しています。

業界の主要企業は一貫して禁煙キャンペーンを支援し、ガムやトローチのような禁煙グッズを定期的に発売しています。これらの製品と効果的な禁煙プログラムを組み合わせることで、個人の禁煙成功の可能性が大幅に高まる。例えば、2022年2月18日、Enorama Pharmaの事業会社であるBetapharm Arzneimittel GmbHが提携し、ドイツでニコチンガムのジェネリック医薬品「ニコチンベータ」を発売しました。このブランドは、ニコチン置換療法（NRT）の利点を強調したジェネリック製品に焦点を当てています。

疾患の有病率の増加がニコチンガムの使用率を押し上げる

喫煙に伴う健康リスクに対する意識の高まりは、禁煙を試みる個人の急増につながっており、これが市場成長の大きな促進要因となっています。さらに、先進国、発展途上国を問わず、リハビリクリニックや医療機関からのニコチン禁煙製品に対する需要が顕著に増加しています。さらに、肺がん、心疾患、呼吸器疾患など、たばこの使用と関連することが多く、世界的に公衆衛生上の大きな負担となっている特定の疾患の有病率が高まっていることも、市場の主な促進要因となっています。これらの要因がニコチンガム市場の潜在的成長に寄与しています。

ニコチンガムに関連する副作用が市場拡大を妨げます

高血圧、めまい、速い心拍、不眠症、過敏症、消化不良、胸やけ、食欲不振、嘔吐、しゃっくりは、ニコチンガムの一般的な副作用の一部です。さらに、頻繁に長時間噛むと吐き気や腹部不快感を誘発します。したがって、予測期間中はこの要因が市場の成長を抑制すると予想されます。

COVID-19影響分析

COVID-19分析には、COVID前シナリオ、COVIDシナリオ、COVID後シナリオが含まれ、価格力学（COVID前シナリオと比較したパンデミック中およびパンデミック後の価格変動を含む）、需給スペクトラム（取引制限、封鎖、およびその後の問題による需要と供給のシフト）、政府の取り組み（政府機関による市場、セクター、産業を活性化させる取り組み）、メーカーの戦略的取り組み（COVID問題を緩和するためにメーカーが行ったことをここで取り上げる）が含まれます。

人工知能分析

ニコチンガムに関する人工知能（AI）分析は、その有効性、ユーザー体験、安全性プロファイル、比較分析に関する貴重な洞察を提供することができます。科学的研究、臨床試験、ユーザーからのフィードバック、ソーシャルメディアデータを分析することで、AIアルゴリズムは禁煙補助におけるニコチンガムの有効性を評価し、推奨用量を最適化することができます。AIはまた、ユーザーの感情を評価し、潜在的な副作用を特定し、ニコチンガムの異なるブランドや製剤を比較することができます。さらにAIは、禁煙補助剤としてニコチンガムを検討している個人の治療計画をパーソナライズし、転帰を予測するための予測モデルを開発することができます。AI分析は貴重な情報を提供しますが、医学的専門知識によって補完されるべきであり、専門家のアドバイスに取って代わるものではありません。

目次

第1章 調査手法と調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場への影響要因
    • 促進要因
      • 禁煙キャンペーンの推進が市場拡大の原動力
    • 抑制要因
      • ニコチンガムに伴う副作用が市場拡大の妨げ
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 2mg
  • 4mg

第8章 用途別

  • 離脱クリニック
  • 医療
  • 個人喫煙者

第9章 流通チャネル別

  • スーパーマーケット/ハイパーマーケット
  • コンビニエンスストア
  • オンラインストア
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Cipla Health Limited
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Perrigo Company Plc.
  • Teva Canada
  • Philip Morris
  • British American Tobacco PLC
  • Johnson & Johnson
  • Novartis AG
  • ITC Limited
  • Major Pharmaceuticals Inc.
  • Lil Drug Store Products Inc.

第13章 付録

目次
Product Code: CPG6480

Market Overview

The Global Nicotine Gum Market reached US$ 1.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.8 billion by 2030. The market is growing at a CAGR of 5.7% during the forecast period 2023-2030. An FDA-approved drug that can assist people in quitting smoking is nicotine gum. It can be used as needed for stronger cravings or every two hours in conjunction with a nicotine patch to prevent withdrawal symptoms which drives the nicotine market size.

Additionally, the gum is a member of the group of drugs known as smoking cessation aids. It is a kind of flavoured chewing gum that releases nicotine into the mouth lining, where it is then absorbed into the smoker's bloodstream and suppresses his or her urge to smoke. Health organisations like the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have advised smokers to give up smoking as a preventative measure in order to recover from COVID-19 infection as a result people started consuming nicotine gum.

Nicotine delivery and absorption play a crucial role in nicotine addiction. Withdrawal symptoms can arise when attempting to quit, as the body becomes dependent on nicotine. Nicotine gum, with its varied flavors, offers a controlled dosing method and aids in managing nicotine withdrawal while enhancing the quitting experience, therbey driving the nicotine gum market size.

Market Dynamics

Promotion of Anti-Smoking Campaigns Drives the Market Expansion.

The growth of this market is propelled by several factors including increasing urbanization, continuous product innovations such as the development of nicotine gums, and extensive research and development efforts. Governments and non-governmental organizations (NGOs) in both emerging and developed nations actively promote the use of smoking cessation products, including nicotine gums and other nicotine replacement products, to help individuals, especially young people, overcome tobacco addiction.

Key players in the industry consistently support anti-smoking campaigns and regularly introduce smoking cessation items like gums and lozenges. By combining these products with effective quit programs, the likelihood of successful smoking cessation among individuals is significantly enhanced. For instance, on February 18, 2022, Betapharm Arzneimittel GmbH, Enorama Pharma's business partnered and launched a generic nicotine chewing gum called Nicotine Beta in Germany. This brand focuses on generic products that emphasize the benefits of nicotine replacement therapy (NRT).

The Increasing Prevalence of Illness Boosts the Usage of Nicotine Gum.

The increasing awareness of the health risks associated with smoking has led to a surge in the number of individuals attempting to quit smoking, which is a significant driver of market growth. Additionally, there has been a notable increase in demand for nicotine cessation products from rehabilitation clinics and medical institutions in both developed and developing countries worldwide. Furthermore, the market is primarily propelled by the growing prevalence of specific illnesses such as lung cancer, cardiac diseases, and respiratory disorders, which are often linked to tobacco use and pose a significant public health burden globally. These factors contribute to the potential growth of the nicotine gum market.

The Side Effects Associated With Nicotine Gum Hamper the Expansion of the Market.

High blood pressure, dizziness, a rapid heartbeat, insomnia, irritability, indigestion, heartburn, loss of appetite, vomiting, and hiccups are some of the common side effects of nicotine gum. Additionally, it induces nausea and abdominal discomfort when chewed frequently and for a long time. Therefore, it is anticipated that this factor will restrain market growth during the forecast period.

COVID-19 Impact Analysis

The COVID-19 Analysis includes Pre-COVID Scenario, COVID Scenario and Post-COVID Scenario along with Pricing Dynamics (Including pricing change during and post-pandemic comparing it with pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), Government Initiatives (Initiatives to revive market, sector or Industry by Government Bodies) and Manufacturers Strategic Initiatives (What manufacturers did to mitigate the COVID issues will be covered here).

Artificial Intelligence Analysis

Artificial intelligence (AI) analysis on nicotine gum can offer valuable insights into its effectiveness, user experiences, safety profile, and comparative analysis. By analyzing scientific studies, clinical trials, user feedback, and social media data, AI algorithms can evaluate the efficacy of nicotine gum in aiding smoking cessation and optimizing dosage recommendations. AI can also assess user sentiment, identify potential side effects, and compare different brands or formulations of nicotine gum. Additionally, AI can develop predictive models to personalize treatment plans and predict outcomes for individuals considering nicotine gum as a smoking cessation aid. While AI analysis provides valuable information, it should be complemented by medical expertise and not replace professional advice.

Segment Analysis

The global nicotine gum market is segmented based on type, application, distribution channel and region.

By Type, the 2mg Segment is Estimated to Have Significant Growth During the Forecast Period

Due to its advantages for light smokers who use fewer than 25 cigarettes per day, the 2mg market category enjoys a substantial market share. Potential customers are still drawn to the readily available 2mg nicotine gums in a range of flavors, which appears to be allowing growth to pick up speed over the predicted period. The effects of nicotine withdrawal and tobacco cravings are reduced and controlled by Nicorette 2mg gum. It is advised to help smokers who try to quit or lower their risk of doing so, to support smokers who are hesitant or unable to stop, and to act as a reasonably safe smoking alternative for both smokers and others around them.

Geographical Analysis

North America is the Fastest Growing Market in the Nicotine Gum Market

In North America, nicotine gum is a popular choice for individuals seeking to quit smoking. With its convenient availability over-the-counter, nicotine gum offers a discreet and accessible form of nicotine replacement therapy (NRT). This region has witnessed a growing demand for nicotine gum as part of smoking cessation efforts, as it provides a convenient and portable option for managing nicotine cravings and withdrawal symptoms.

Additionally, the availability of various nicotine gum flavors in North America caters to diverse preferences, further contributing to its popularity among those looking to quit smoking in the region. For instance, on May 17, 2021, North America Generics, Dr. Reddy's Laboratories, launched 2 mg and 4 mg, the store brand version of Nicorette Lozenges in the U.S. With the introduction of Nicotine Polacrilex Lozenges, the OTC category of smoking cessation products is still committed

Competitive Landscape

The major global players in the market include: Cipla Health Limited, Perrigo Company Plc., Teva Canada, Philip Morris, British American Tobacco PLC, Johnson & Johnson, Novartis AG, ITC Limited, Major Pharmaceuticals Inc. and Lil Drug Store Products Inc.

Why Purchase the Report?

  • To visualize the global nicotine gum market segmentation based on type, application, distribution channel and region, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities in the market by analyzing trends and co-development.
  • Excel data sheet with numerous data points of nicotine gum market-level with all segments.
  • The PDF report consists of cogently put-together market analysis after exhaustive qualitative interviews and in-depth market study.
  • Product mapping is available as Excel consists of key products of all the major market players.

The global nicotine gum market report would provide approximately 61 tables, 58 figures and 190 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet, by Type
  • 3.2. Market Snippet, by Application
  • 3.3. Market Snippet, by Distribution Channel
  • 3.4. Market Snippet, by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Promotion of anti-smoking campaigns drives the market expansion.
    • 4.1.2. Restraints
      • 4.1.2.1. The side effects associated with nicotine gum hamper the expansion of the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19 on the Market
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. 2 mg *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. 4 mg

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Withdrawal Clinics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Medical Practice
  • 8.4. Individual Smokers

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Supermarkets/Hypermarkets*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Convenience Stores
  • 9.4. Online Stores
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Cipla Health Limited*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Perrigo Company Plc.
  • 12.3. Teva Canada
  • 12.4. Philip Morris
  • 12.5. British American Tobacco PLC
  • 12.6. Johnson & Johnson
  • 12.7. Novartis AG
  • 12.8. ITC Limited
  • 12.9. Major Pharmaceuticals Inc.
  • 12.10. Lil Drug Store Products Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us